ACA market news: Cigna expanding, Centene scaling back

One of the five largest health insurers in the U.S. plans on expanding its offerings on health insurance marketplaces for 2017, going in the opposite direction of rivals Humana and UnitedHealthcare when it comes to participation on Affordable Care Act exchanges.

Cigna announced July 26 it has notified insurance regulators about plans to offer coverage on the exchanges in Chicago, the Raleigh-Durham market of North Carolina, as well as Richmond, Virginia, and northern parts of the state, according to The Hill and the Chicago Tribune.

Cigna had offered plans in seven states through the marketplaces in 2016. A company spokesperson told Fox Business in April that it was looking into expanding into “a few new geographies” for next year.  

Notably, the move comes days after the U.S. Department of Justice had filed antitrust lawsuits against Cigna’s proposed acquisition by Anthem and the proposed Aetna-Humana merger. Humana followed the news with its own announcement that it was dropping out of several ACA markets.

Fitting with the theme of conflicting expansions and contractions of different insurers’ 2017 ACA participation, on the same day Cigna announced it was moving into new markets, Centene announced in its latest earnings report that it will leave significantly reduce its marketplace presence in Arizona, offering coverage in only one county.

While Centene said its overall performance on the marketplaces is strong, its position is complicated by its March acquisition of HealthNet, which had suffered heavy losses on exchanges in California and Arizona.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.